← Leaderboards
Anna E Vilgelm
Ohio State University
$2,524,271
Attributed
$2,748,554
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $665.4K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,748,554 · 2
By mechanism
R37$2,412,129 · 1
R21$336,425 · 1
Top collaborators
- Alex C. Kim1 shared
- Arjun Mittra1 shared
Most similar at Ohio State University
Same institution · by research overlap
- William E. Carson$27,905,247
- Craig J Burd$3,860,523
- Miguel Angel Villalona$9,621,601
- Pan Zheng$7,391,253
- Tatiana M Oberyszyn$5,838,919
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseCellsImproved OutcomeTumorCombined Modality TherapyDoseFlow CytometryImmune Checkpoint InhibitorNeoplastic CellStandard Of CareNovel Therapeutic InterventionNeoplasm MetastasisImmuneAnti-Tumor Immune ResponseBindingAnti-Pd-L1Antigen PresentationBcl2 GeneAurora KinaseAntigensClinical DevelopmentCheckpoint TherapyCell AgingChemokine
Grant awards (8)
Combining senescence-inducing and senolytic agents to improve melanoma therapy$338,882
R37 · FY2025 · CA · contact PI
Combining senescence-inducing and senolytic agents to improve melanoma therapy$321,938
R37 · FY2024 · CA · contact PI
A phase-1 trial of intraperitoneal 5-fluorouracil and oxaliplatin in patients with colorectal cancer and unresectable peritoneal metastasis.$336,425
R21 · FY2023 · CA
Combining senescence-inducing and senolytic agents to improve melanoma therapy$328,942
R37 · FY2023 · CA · contact PI
Combining senescence-inducing and senolytic agents to improve melanoma therapy$342,876
R37 · FY2022 · CA · contact PI
Combining senescence-inducing and senolytic agents to improve melanoma therapy$349,980
R37 · FY2021 · CA · contact PI
Combining senescence-inducing and senolytic agents to improve melanoma therapy$357,067
R37 · FY2020 · CA · contact PI
Combining senescence-inducing and senolytic agents to improve melanoma therapy$372,444
R37 · FY2019 · CA · contact PI